Cargando…

The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01

The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacod...

Descripción completa

Detalles Bibliográficos
Autores principales: Landin, Erik J.B., Williams, Christopher, Ryan, Sara A., Bochel, Alice, Akter, Nahida, Redfield, Christina, Sessions, Richard B., Dedi, Neesha, Taylor, Richard J., Crump, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671939/
https://www.ncbi.nlm.nih.gov/pubmed/34758357
http://dx.doi.org/10.1016/j.jbc.2021.101392
_version_ 1784615253150007296
author Landin, Erik J.B.
Williams, Christopher
Ryan, Sara A.
Bochel, Alice
Akter, Nahida
Redfield, Christina
Sessions, Richard B.
Dedi, Neesha
Taylor, Richard J.
Crump, Matthew P.
author_facet Landin, Erik J.B.
Williams, Christopher
Ryan, Sara A.
Bochel, Alice
Akter, Nahida
Redfield, Christina
Sessions, Richard B.
Dedi, Neesha
Taylor, Richard J.
Crump, Matthew P.
author_sort Landin, Erik J.B.
collection PubMed
description The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacodynamics of numerous small molecule therapeutics. Staurosporine, and its hydroxylated forms UCN-01 and UCN-02, are kinase inhibitors that have been investigated at length as antitumour compounds. Despite their potency, these compounds display poor pharmokinetics due to binding to both AGP variants, AGP1 and AGP2. The recent renewed interest in UCN-01 as a cytostatic protective agent prompted us to solve the structure of the AGP2–UCN-01 complex by X-ray crystallography, revealing for the first time the precise binding mode of UCN-01. The solution NMR suggests AGP2 undergoes a significant conformational change upon ligand binding, but also that it uses a common set of sidechains with which it captures key groups of UCN-01 and other small molecule ligands. We anticipate that this structure and the supporting NMR data will facilitate rational redesign of small molecules that could evade AGP and therefore improve tissue distribution.
format Online
Article
Text
id pubmed-8671939
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-86719392021-12-22 The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 Landin, Erik J.B. Williams, Christopher Ryan, Sara A. Bochel, Alice Akter, Nahida Redfield, Christina Sessions, Richard B. Dedi, Neesha Taylor, Richard J. Crump, Matthew P. J Biol Chem Research Article The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacodynamics of numerous small molecule therapeutics. Staurosporine, and its hydroxylated forms UCN-01 and UCN-02, are kinase inhibitors that have been investigated at length as antitumour compounds. Despite their potency, these compounds display poor pharmokinetics due to binding to both AGP variants, AGP1 and AGP2. The recent renewed interest in UCN-01 as a cytostatic protective agent prompted us to solve the structure of the AGP2–UCN-01 complex by X-ray crystallography, revealing for the first time the precise binding mode of UCN-01. The solution NMR suggests AGP2 undergoes a significant conformational change upon ligand binding, but also that it uses a common set of sidechains with which it captures key groups of UCN-01 and other small molecule ligands. We anticipate that this structure and the supporting NMR data will facilitate rational redesign of small molecules that could evade AGP and therefore improve tissue distribution. American Society for Biochemistry and Molecular Biology 2021-11-07 /pmc/articles/PMC8671939/ /pubmed/34758357 http://dx.doi.org/10.1016/j.jbc.2021.101392 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Landin, Erik J.B.
Williams, Christopher
Ryan, Sara A.
Bochel, Alice
Akter, Nahida
Redfield, Christina
Sessions, Richard B.
Dedi, Neesha
Taylor, Richard J.
Crump, Matthew P.
The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title_full The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title_fullStr The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title_full_unstemmed The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title_short The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
title_sort structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound ucn-01
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671939/
https://www.ncbi.nlm.nih.gov/pubmed/34758357
http://dx.doi.org/10.1016/j.jbc.2021.101392
work_keys_str_mv AT landinerikjb thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT williamschristopher thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT ryansaraa thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT bochelalice thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT akternahida thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT redfieldchristina thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT sessionsrichardb thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT dedineesha thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT taylorrichardj thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT crumpmatthewp thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT landinerikjb structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT williamschristopher structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT ryansaraa structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT bochelalice structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT akternahida structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT redfieldchristina structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT sessionsrichardb structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT dedineesha structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT taylorrichardj structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01
AT crumpmatthewp structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01